Through the development of selective small-molecule inhibitors targeting HIF2α/ARNT dimerization, potentially suitable drugs are available, which are of particular interest for the more aggressive pseudohypoxic PPGLs and neuroblastomas. This evidence concerns the gene EPAS1 and neuroblastoma.